Vensica
Founded 2014 · 10 employees on LinkedIn · 7 known investors
Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall. The company focuses on urology therapeutics for unmet medical needs.
Also known as Vensica Medical · Vensica Medical Ltd. · Vensica Therapeutics
Founders & leadership
Vensica was founded in 2014 by Avner Geva and Avi Eftel.
Investors · 7
Also in the syndicate · 5
Company profile
researched Aug 2026Vensica Medical (also referred to as Vensica Therapeutics) is a clinical-stage urology therapeutics company developing localized bladder drug delivery. Its lead program, ViXe, pairs Xeomin, an FDA-approved and uniquely purified botulinum toxin A licensed from Merz, with Vibe, a needle-free ultrasound-based delivery device. Vibe generates cavitation bubbles to drive drugs across the natural barriers of the urinary bladder, microinjecting them into the bladder wall for what the company describes as uniform, controlled and localized administration.
The initial indication is overactive bladder (OAB), where the intended benefit versus conventional intravesical botulinum toxin injection is a less invasive, needle-free procedure. Beyond OAB, the company positions Vibe as a platform capable of delivering a range of bladder-targeted therapies and biologics for additional urologic indications, and maintains a clinical pipeline built around that platform.
Leadership includes co-founders Avner Geva (CEO) and Avi Eftel (CTO), with Roger R. Dmochowski, MD of Vanderbilt University as Chief Medical Officer and Ken Berlin as Executive Chairman. The board includes Ido Zairi of the Israel Biotech Fund, Stefan Albrecht of Merz Therapeutics, Todd Dollinger, Michael Ingber, MD, and Sofia Gerard, and the scientific advisory board includes urology professors from Vanderbilt University, the Cleveland Clinic and Meir Medical Center.
Founding story
The company was founded in 2014 by Avner Geva together with The Trendlines Group, and was established through the incubator programs of The Trendlines Group and the Israel Innovation Authority.
Business model
Vensica is a development-stage therapeutics and device company advancing a combination product through clinical trials rather than selling a commercial product. It in-licensed a marketed neurotoxin (Xeomin) from Merz for needle-free therapeutic use in several urologic indications and is funding clinical development through venture and strategic investment.
Traction
The company reported a successful Phase IIa clinical trial in September 2024 and cumulative funding of roughly $30 million since its 2014 founding. It had five employees at the time of the October 2024 round. Its site reports FDA IND clearance in April 2026 for a Phase 2 study of ViXe.
Latest developments
In October 2024 Vensica announced the close of an $11 million round led by the Israel Biotech Fund with Merz and Laborie, earmarked for Phase 2 clinical trials in the United States and Europe, following a successful Phase IIa trial reported in September 2024. The company's website reports FDA IND clearance in April 2026 to begin a Phase 2 study of ViXe for OAB.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Vensica describes Vibe as the first needle-free botulinum toxin A delivery device, positioning ViXe against conventional needle-based intravesical botulinum toxin injection for overactive bladder.
Technology
Vibe is an ultrasound-based drug delivery platform that generates cavitation bubbles to microinject drugs through the natural barriers of the urinary bladder and into the bladder wall, enabling needle-free, localized and uniform delivery of medications and biologics. ViXe combines this device with Xeomin, a purified botulinum toxin A.
Go-to-market
Development is being advanced in partnership with strategic corporate investors: Merz, which licenses Xeomin and provides clinical development support, and Laborie, a urology medical device company. Vensica holds exclusive rights to Xeomin for needle-free therapeutic application in several urologic indications.
Patients with overactive bladder and, prospectively, other urinary bladder indications, treated by urologists and pelvic medicine specialists.
Geography
Coverage variously places the company in Brooklyn/New York City and Tel Aviv, Israel, with an office in Herzliya, Israel. Planned Phase 2 clinical trials span the United States and Europe.
History
Vensica was founded in 2014 by Avner Geva and The Trendlines Group, and was established within the incubator program of The Trendlines Group (SGX: 42T; OTCQX: TRNLY) and the Israel Innovation Authority. In 2021 it signed a strategic license and collaboration agreement with Merz Therapeutics covering botulinum neurotoxin A (Xeomin) for needle-free urological use, and closed a $16 million round led by the Israel Biotech Fund that November; the company's own site describes a $19 million investment closed in February 2022 to carry it through Phase II. In September 2024 it reported completing a Phase IIa clinical trial, and in October 2024 announced an additional $11 million round. By that point it reported having raised approximately $30 million in total. The company's site reports FDA IND clearance in April 2026 to begin a Phase 2 study of ViXe.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsVensica received FDA IND clearance to begin a Phase 2 study of ViXe, its needle-free Xeomin delivery system for overactive bladder.
Round led by Israel Biotech Fund with strategic partners Merz and Laborie, funding Phase 2 clinical trials for overactive bladder in the United States and Europe.
$11M source ↗
Vensica reported meeting its milestones with a successful Phase IIa clinical trial alongside continued investment of $11M.
Company-reported round intended to take Vensica through Phase II.
$19M source ↗
Round to support multicenter Phase II clinical trials in Europe and the USA and expand the Israeli workforce.
$16M source ↗
Vensica and Merz launched a partnership for needle-free treatment of overactive bladder, under which Vensica licensed Merz's botulinum neurotoxin A (Xeomin) for needle-free use in urological procedures and secured exclusive rights in several urologic indications plus Merz clinical development support.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Vensicavensica.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vensica do?
- Urology therapeutics company developing ViXe, a needle-free ultrasound system delivering Xeomin into the bladder wall for overactive bladder.
- Who founded Vensica?
- Vensica was founded by Avner Geva, Avi Eftel in 2014.
- Who are Vensica's investors?
- Vensica's investors include Israel Biotech Fund, Trendlines Group.